Press releases

We are pleased to welcome Tobias Assander to Disruptive Pharma as Formulite® Manufacturing and Process Development Lead. Tobias brings broad experience from the pharmaceutical industry and will lead activities related to process development, scale-up and manufacturing of Formulite®. His role will be important as we continue strengthening...

Evelina Meurling and Ellen Brunzell will represent Disruptive Pharma at the SweDeliver Summit 2026, an annual meeting bringing together academia and industry in drug delivery and pharmaceutical development. The SweDeliver network provides an important forum for exchanging experience, sharing perspectives and staying closely connected to developments...

Disruptive Pharma will attend Nordic Life Science Days in Stockholm, where Peter Åsberg and Martina Ferneman will meet with potential partners from the pharmaceutical and biotechnology industries. During the conference, we look forward to discussing Formulite®, oral drug development and formulation challenges where our technology can create...

Friday marked a special moment for Disruptive Pharma, as colleagues, Board members and guests gathered at Nasdaq Stockholm to celebrate the company's new chapter as a listed company. The opening bell ceremony was an opportunity to reflect on how far Disruptive Pharma and Formulite® have come – from many years of scientific research and...

Disruptive Pharma AB (publ), formerly Guard Therapeutics International AB (publ), (“Disruptive Pharma” or the “Company”) will ring the opening bell at Nasdaq Stockholm on 21 August 2026. On the same day, the Company’s shares will begin trading under the new ticker symbol DPHA, replacing GUARD. The bell-ringing ceremony marks the...